Drug prices in the U. S. are already approaching a crisis point for many patients unable to afford their prices, often despite being insured. These examples indicate how serious this problem has become:
The use of prescription drugs by Americans, partly driven by direct-to-consumer advertising since the 1990s, has reached an all-time high.
Impact of data exclusivity in Ukraine on access to affordable generic version of sofosbuvir ( direct acting antiviral – DAA used for Hepatitis C treatment)
Chronology of events/facts
- Pharmasset originally developed Sofosbuvir. Gilead Sciences acquired Pharmasset including its Hepatititis C compounds sofosbuvir for $11.2 billion in 2012.
- December 2013 USFDA approves sofosbuvir for inclusion in Hepatitis C treatment regimens, dramatically improving cure rates for the disease. Continue reading
By Tahir Amin, The Huffington Post | August 17, 2016
The cost of dozens of brand-name drugs have nearly doubled in just the past five years. Public outrage over drug prices extends from Capitol Hill to the presidential candidates to patients. In response, pharmaceutical executives are spending more on lobbying and marketing. Yet for all this attention, most of the proposed solutions for reducing prescription drug costs—tougher negotiations, appeals for transparent R&D costs or investigations into insurers—miss one of the primary sources of the problem: the way we award patents. Continue reading
Authors: Joel Lexchin & Deborah Gleeson| Publication: Sage Journals
Int J Health Serv August 11, 20160020731416662612
The Trans Pacific Partnership Agreement (TPP) is a large regional trade agreement involving 12 countries. It was signed in principle in February 2016 but has not yet been ratified in any of the participating countries. The TPP provisions place a range of constraints on how governments regulate the pharmaceutical sector and set prices for medicines. This article presents a prospective policy analysis of the possible effects of the TPP on these two points in Canada and Australia. Continue reading
By Prabhas Ranjan, The Wire| February 2, 2016
Pricked after being sued by foreign investors under different bilateral investment treaties (BIT), India has adopted a new model. But it could impact the ongoing India-US BIT negotiations.
Provoked by foreign investors suing India under different bilateral investment treaties (BITs), the government recently adopted a new model BIT. Countries develop a model BIT to use as a template to negotiate investment treaties, but on its own, a model BIT has very limited legal value. The 2015 model BIT replaces the 2003 model, which was fairly investor-friendly. Most of India’s existing BITs, signed with more than 70 countries, are based on the 2003 model. The adoption of the new model BIT heralds a new era in India’s engagement with foreign investment and investment treaty practice. Continue reading
Source: The Hindu | August 16, 2016
Regional Comprehensive Economic Partnership (RCEP) deal could hit supply of cheap Indian drugs
As the next round of Regional Comprehensive Economic Partnership (RCEP) trade talks begin in Vietnam on Monday, humanitarian aid organisation Médecins Sans Frontières (MSF) has called for the removal of intellectual property provisions — known as the TRIPS-plus provisions — from the agreement. The talks are scheduled for August 15-19. Continue reading
India may offer tariff reduction in a much higher number of commodities to China with whom it has a staggering $52.7 billion trade deficit
By Asit Ranjan Mishra, Live Mint | August 9, 2016
New Delhi: In a major shift in stance that may benefit China, India has agreed to provide similar tariff cuts to all Regional Comprehensive Economic Partnership agreement (RCEP) member countries with limited deviation. Continue reading